Tilray Brands (TLRY) Cash from Financing Activities (2017 - 2026)
Tilray Brands' (TLRY) quarterly Cash from Financing Activities came in at $68.2 million in Q2 2026, up 309.65% YoY from $16.6 million in Q2 2025, and up 1429.45% on a QoQ basis from -$5.1 million in Q1 2026.
Tilray Brands (TLRY) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Cash from Financing Activities data on file, last reported at $68.2 million in Q2 2026.
- Quarterly Cash from Financing Activities rose 309.65% year-over-year to $68.2 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $131.0 million (down 1.88% YoY) and the FY2026 annual result came in at $131.0 million, down 1.88% from the prior year.
- Cash from Financing Activities rose to $68.2 million in Q2 2026, from -$5.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $161.8 million in Q2 2022 to a low of -$85.4 million in Q4 2023.
- A 5-year average of $23.1 million and a median of $15.3 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 1639.86% — and 2024, when it slumped 346.72%.
- Tracing TLRY's Cash from Financing Activities over 5 years: stood at -$57.3 million in 2022, then tumbled by 49.1% to -$85.4 million in 2023, then surged by 144.75% to $38.2 million in 2024, then increased by 25.91% to $48.1 million in 2025, then soared by 41.73% to $68.2 million in 2026.
- The last three Cash from Financing Activities figures came in at $68.2 million (Q2 2026), -$5.1 million (Q1 2026), and $48.1 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn | 68.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 68.17 Mn |
| May 31, 2026 | 68.17 Mn |
| Feb 28, 2026 | -5.13 Mn |
| Feb 28, 2026 | -5.13 Mn |
| Nov 30, 2025 | 48.10 Mn |
| Nov 30, 2025 | 48.10 Mn |
| Aug 31, 2025 | 19.85 Mn |
| Aug 31, 2025 | 19.85 Mn |
| May 31, 2025 | 16.64 Mn |
| May 31, 2025 | 16.64 Mn |
| Feb 28, 2025 | 18.07 Mn |
| Feb 28, 2025 | 18.07 Mn |
| Nov 30, 2024 | 38.20 Mn |
| Nov 30, 2024 | 38.20 Mn |
| Aug 31, 2024 | 60.59 Mn |
| Aug 31, 2024 | 60.59 Mn |
| May 31, 2024 | 7.07 Mn |
| May 31, 2024 | 7.07 Mn |
| Feb 29, 2024 | -10.91 Mn |
| Feb 29, 2024 | -10.91 Mn |